Mergers & Acquisitions ·
Harrow acquires TYRVAYA rights for $30M upfront plus up to $70M in milestones
HROWHarrow, Inc.
Harrow completed the acquisition of worldwide commercialization rights to TYRVAYA (varenicline solution) nasal spray from Viatris, excluding Japan. Harrow paid $30 million in cash at closing and is obligated to pay up to $70 million in contingent milestone payments based on net sales thresholds through December 2029. The deal adds a differentiated, drop-free treatment option for dry eye disease to Harrow's portfolio, complementing its existing product VEVYE. Approximately 40 personnel from Viatris are expected to join Harrow's commercial team in the fourth quarter of 2026. Harrow expects TYRVAYA to contribute more than $30 million in revenue in 2027. Harrow is a leading provider of ophthalmic disease management solutions in North America.